Brenton M Wong1, Jeffrey J Perry1,2,3, Wei Cheng2, Bo Zheng1, Kevin Guo1, Monica Taljaard2,3, Allan C Skanes4, Ian G Stiell5,6,7. 1. Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada. 2. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada. 4. Division of Cardiology, Western University, London, ON, Canada. 5. Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada. istiell@ohri.ca. 6. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. istiell@ohri.ca. 7. Clinical Epidemiology Unit, The Ottawa Hospital, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada. istiell@ohri.ca.
Abstract
BACKGROUND: Recent studies have presented concerning data on the safety of cardioversion for acute atrial fibrillation and flutter. We conducted this meta-analysis to evaluate the effect of oral anticoagulation use on thromboembolic events post-cardioversion of low-risk acute atrial fibrillation and flutter patients of < 48 h in duration. METHODS: We searched MEDLINE, Embase, and Cochrane from inception through February 6, 2020 for studies reporting thromboembolic events post-cardioversion of acute atrial fibrillation and flutter. Main outcome was thromboembolic events within 30 days post-cardioversion. Primary analysis compared thromboembolic events based on oral anticoagulation use versus no oral anticoagulation use. Secondary analysis was based on baseline thromboembolic risk. We performed meta-analyses where 2 or more studies were available, by applying the DerSimonian-Laird random-effects model. Risk of bias was assessed with the Quality in Prognostic Studies tool. RESULTS: Of 717 titles screened, 20 studies met inclusion criteria. Primary analysis of seven studies with low risk of bias demonstrated insufficient evidence regarding the risk of thromboembolic events associated with oral anticoagulation use (RR = 0.82 where RR < 1 suggests decreased risk with oral anticoagulation use; 95% CI 0.27 to 2.47; I2 = 0%). Secondary analysis of 13 studies revealed increased risk of thromboembolic events with high baseline thromboembolic risk (RR = 2.25 where RR > 1 indicates increased risk with higher CHADS2 or CHA2DS2-VASc scores; 95% CI 1.25 to 4.04; I2 = 0%). CONCLUSION: Primary analysis revealed insufficient evidence regarding the effect of oral anticoagulation use on thromboembolic events post-cardioversion of low-risk acute atrial fibrillation and flutter, though the event rate is low in contemporary practice. Our findings can better inform patient-centered decision-making when considering 4-week oral anticoagulation use for acute atrial fibrillation and flutter patients.
BACKGROUND: Recent studies have presented concerning data on the safety of cardioversion for acute atrial fibrillation and flutter. We conducted this meta-analysis to evaluate the effect of oral anticoagulation use on thromboembolic events post-cardioversion of low-risk acute atrial fibrillation and flutter patients of < 48 h in duration. METHODS: We searched MEDLINE, Embase, and Cochrane from inception through February 6, 2020 for studies reporting thromboembolic events post-cardioversion of acute atrial fibrillation and flutter. Main outcome was thromboembolic events within 30 days post-cardioversion. Primary analysis compared thromboembolic events based on oral anticoagulation use versus no oral anticoagulation use. Secondary analysis was based on baseline thromboembolic risk. We performed meta-analyses where 2 or more studies were available, by applying the DerSimonian-Laird random-effects model. Risk of bias was assessed with the Quality in Prognostic Studies tool. RESULTS: Of 717 titles screened, 20 studies met inclusion criteria. Primary analysis of seven studies with low risk of bias demonstrated insufficient evidence regarding the risk of thromboembolic events associated with oral anticoagulation use (RR = 0.82 where RR < 1 suggests decreased risk with oral anticoagulation use; 95% CI 0.27 to 2.47; I2 = 0%). Secondary analysis of 13 studies revealed increased risk of thromboembolic events with high baseline thromboembolic risk (RR = 2.25 where RR > 1 indicates increased risk with higher CHADS2 or CHA2DS2-VASc scores; 95% CI 1.25 to 4.04; I2 = 0%). CONCLUSION: Primary analysis revealed insufficient evidence regarding the effect of oral anticoagulation use on thromboembolic events post-cardioversion of low-risk acute atrial fibrillation and flutter, though the event rate is low in contemporary practice. Our findings can better inform patient-centered decision-making when considering 4-week oral anticoagulation use for acute atrial fibrillation and flutter patients.
Authors: John H Burton; David R Vinson; Kate Drummond; Tania D Strout; Henry C Thode; Jeff J McInturff Journal: Ann Emerg Med Date: 2004-07 Impact factor: 5.721
Authors: Atul Verma; John A Cairns; L Brent Mitchell; Laurent Macle; Ian G Stiell; David Gladstone; Michael Sean McMurtry; Stuart Connolly; Jafna L Cox; Paul Dorian; Noah Ivers; Kori Leblanc; Stanley Nattel; Jeff S Healey Journal: Can J Cardiol Date: 2014-08-13 Impact factor: 5.223
Authors: Ian G Stiell; Catherine M Clement; Jeffrey J Perry; Christian Vaillancourt; Cheryl Symington; Garth Dickinson; David Birnie; Martin S Green Journal: CJEM Date: 2010-05 Impact factor: 2.410
Authors: Federico Gentile; Abdou Elhendy; Buoy K Khandheria; James B Seward; Christine M Lohse; Win-Kuang Shen; Kent R Bailey; Samantha C Montgomery; Kelli N Burger; A Jamil Tajik Journal: Mayo Clin Proc Date: 2002-09 Impact factor: 7.616
Authors: Mark M Gallagher; Brian J Hennessy; Nils Edvardsson; Ceara M Hart; Muriel S Shannon; Owen A Obel; Naab M Al-Saady; A John Camm Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: Wyatt W Decker; Peter A Smars; Lekshmi Vaidyanathan; Deepi G Goyal; Eric T Boie; Latha G Stead; Douglas L Packer; Thomas D Meloy; Andy J Boggust; Luis H Haro; Dennis A Laudon; Joseph K Lobl; Annie T Sadosty; Raquel M Schears; Nicola E Schiebel; David O Hodge; Win-Kuang Shen Journal: Ann Emerg Med Date: 2008-03-14 Impact factor: 5.721